What is CUSIP 40637H109?

CUSIP 40637H109 is the security identifier used in SEC filing datasets for HALO - HALOZYME THERAPEUTICS, INC. - Common Stock.

Who owns HALO - HALOZYME THERAPEUTICS, INC. - Common Stock based on 13F filings?

630 institutions reported positions in HALO - HALOZYME THERAPEUTICS, INC. - Common Stock as of Q1 2026. Open the latest holders period and ownership history tables on this page for position-level details.

Security Snapshot

HALOZYME THERAPEUTICS, INC. - Common Stock (HALO) Institutional Ownership

CUSIP: 40637H109

13F Institutional Holders and Ownership History from Q1 2014 to Q1 2026

Latest Period

Q1 2026

Institutions Reporting

630

Shares (Excl. Options)

120,100,942

Price

$64.63

Save this security page for your next review

Keep this CUSIP in your watchlists so you can revisit quarter changes from one place. If you create an account from here, we will bring you back after verification.

Create free account and return here Sign in and return here Review latest holder period

Type / Class: Equity / Common Stock
Symbol: HALO on Nasdaq
Shares outstanding: 118,494,184
Price per share: $63.86
All holders as of 31 Mar 2026: Q1 2026
Total 13F shares: 120,100,942
Total reported value: $7,764,348,736
% of total 13F portfolios: 0.01%
Share change: -2,479,018
Value change: -$172,707,864
Number of holders: 630
Price from insider filings: $63.86

Reported Shares, Excluding Options vs Price

Reported Value, Excluding Options

Total Investors

Key facts

HALO - HALOZYME THERAPEUTICS, INC. - Common Stock is tracked under CUSIP 40637H109.
630 institutions reported positions in Q1 2026.
3 significant owners is listed from Schedule 13D/13G reporting.

Change

Holder count moved from 612 to 630 between Q4 2025 and Q1 2026.
Reported value moved from $8,286,728,395 to $7,764,348,736.

Research use

You can quickly see who holds this security, then open quarter and manager detail pages for full evidence.
13F and Schedule 13D/13G sections are kept together so you can cross-check institutional and beneficial ownership context.

Evidence

Source: SEC Form 13F

Latest holder context comes from 630 institutions filings for Q1 2026.

Open SEC Evidence

Security key

40637H109

Latest holder period

Q1 2026

13F holders

630

13D/G owners

CIK / CUSIP context first

Open Q1 2026 holders HALO full holder history HALOZYME THERAPEUTICS, INC. SEC filings HALOZYME THERAPEUTICS, INC. company facts HALOZYME THERAPEUTICS, INC. insider transactions

Broader feeds

Latest 13F filings Latest 13D/G filings All securities

Recent Quarterly Holder Reports

Open recent reporting periods for CUSIP 40637H109:

Q1 2026 (630 holders) Q4 2025 (612 holders) Q3 2025 (596 holders) Q2 2025 (541 holders) Q1 2025 (543 holders) Q4 2024 (500 holders) Q3 2024 (503 holders) Q2 2024 (449 holders) Q1 2024 (409 holders) Q4 2023 (409 holders)

Significant Owners of HALOZYME THERAPEUTICS, INC. - Common Stock (HALO) based on Schedule 13D/G filings

Filer	Ownership	Change %	Holdings Value	Net Change	Nb Shares	Change %	Reporting Name	Report Period
BlackRock, Inc.	10%	-22%	$656,091,846	-$183,727,565	12,612,300	-22%	BlackRock, Inc.	30 Jun 2025
VANGUARD CAPITAL MANAGEMENT LLC	5.2%		$398,996,343		6,173,547		Vanguard Capital Management	31 Mar 2026
STATE STREET CORP	4.9%		$358,640,665		6,053,007		STATE STREET CORPORATION	31 Mar 2025

As of 31 Mar 2026, 630 institutional investors reported holding 120,100,942 shares of HALOZYME THERAPEUTICS, INC. - Common Stock (HALO). This represents 101% of the company’s total 118,494,184 outstanding shares.

Top 25 Institutional Shareholders

The largest institutional shareholders of HALOZYME THERAPEUTICS, INC. - Common Stock (HALO) together control 60% of the company’s outstanding shares — a level of ownership often associated with strong institutional conviction and long‑term capital commitment.

Institution	Ownership %	Shares Held	Share Change %	Portfolio %	Holdings Value
BlackRock, Inc.	11%	13,265,053	+0.85%	0.02%	$857,320,342
VANGUARD CAPITAL MANAGEMENT LLC	4.4%	5,271,218	0%	0.01%	$340,678,819
VANGUARD PORTFOLIO MANAGEMENT LLC	4.4%	5,249,206	0%	0.02%	$339,256,184
STATE STREET CORP	4.2%	4,937,854	-3.6%	0.01%	$319,133,504
Invesco Ltd.	3.4%	4,012,494	+10%	0.04%	$259,327,487
BANK OF AMERICA CORP /DE/	2.5%	2,913,109	+6.6%	0.01%	$188,274,222
Boston Partners	2.3%	2,683,683	+451%	0.18%	$173,432,991
MORGAN STANLEY	2.2%	2,562,308	-3.6%	0.01%	$165,602,104
WILLIAM BLAIR INVESTMENT MANAGEMENT, LLC	2.1%	2,525,975	+37%	0.54%	$163,253,764
GEODE CAPITAL MANAGEMENT, LLC	2.1%	2,505,786	+3%	0.01%	$161,982,673
SNYDER CAPITAL MANAGEMENT L P	2%	2,323,077	-3.2%	2.9%	$150,140,467
DIMENSIONAL FUND ADVISORS LP	1.8%	2,079,827	-1.2%	0.03%	$134,398,148
ARROWSTREET CAPITAL, LIMITED PARTNERSHIP	1.6%	1,918,149	-40%	0.07%	$123,969,970
D. E. Shaw & Co., Inc.	1.6%	1,868,708	+13%	0.1%	$120,774,599
ALLIANCEBERNSTEIN L.P.	1.5%	1,736,501	-5.4%	0.04%	$116,866,517
ROYAL LONDON ASSET MANAGEMENT LTD	1.4%	1,610,553	+17%	0.22%	$104,090,040
JUPITER ASSET MANAGEMENT LTD	1.4%	1,608,256	+2.5%	0.55%	$103,941,586
TWO SIGMA INVESTMENTS, LP	1.3%	1,584,961	+121%	0.09%	$102,436,029
WELLS FARGO & COMPANY/MN	1.3%	1,535,737	+9.3%	0.02%	$99,254,713
FIRST TRUST ADVISORS LP	1.3%	1,482,340	+47%	0.07%	$95,803,603
FULLER & THALER ASSET MANAGEMENT, INC.	1.2%	1,465,283	+6.2%	0.32%	$94,701,251
GW&K Investment Management, LLC	1.2%	1,393,875	+11%	0.79%	$90,086,000
LSV ASSET MANAGEMENT	1.2%	1,371,558	+5.4%	0.19%	$88,644,000
MIZUHO MARKETS AMERICAS LLC	1.1%	1,323,544	+4.3%	2.4%	$85,540,649
CHARLES SCHWAB INVESTMENT MANAGEMENT INC	1.1%	1,289,533	+3.8%	0.01%	$83,342,518

Institutional Holders of HALOZYME THERAPEUTICS, INC. - Common Stock (HALO) across Reporting Periods

Period	Reported Shares, Excl. Options	Value, Excl. Options	Value Change	Puts Notional Value	Calls Notional Value	Price (Median)	Investors
2026 Q1	120,100,942	$7,764,348,736	-$172,707,864	$16,079,944	$20,616,970	$64.63	630
2025 Q4	123,171,179	$8,286,728,395	+$134,974,984	$14,711,780	$23,783,820	$67.30	612
2025 Q3	119,220,823	$8,742,315,256	+$226,173,219	$33,387,227	$45,900,521	$73.34	596
2025 Q2	116,352,424	$6,053,937,391	-$203,145,554	$20,186,660	$21,223,655	$52.02	541
2025 Q1	120,489,904	$7,687,315,257	-$91,368,957	$7,218,048	$20,400,537	$63.81	543
2024 Q4	122,458,776	$5,856,815,335	-$193,231,691	$12,404,405	$31,914,579	$47.81	500
2024 Q3	125,205,134	$7,161,621,740	+$188,148,727	$10,299,069	$16,820,190	$57.24	503
2024 Q2	122,186,529	$6,397,611,292	-$49,238,862	$3,471,468	$10,864,700	$52.36	449
2024 Q1	123,583,310	$5,026,636,534	-$29,500,183	$5,687,064	$8,795,016	$40.68	409
2023 Q4	124,680,353	$4,614,991,205	+$45,612,024	$4,390,848	$10,230,528	$36.96	409
2023 Q3	123,213,224	$4,707,973,255	-$3,726,561	$5,439,680	$12,174,340	$38.20	389
2023 Q2	123,025,101	$4,439,170,134	-$50,628,033	$19,127,921	$13,039,305	$36.07	368
2023 Q1	124,051,427	$4,736,116,144	-$286,882,621	$3,309,137	$8,581,868	$38.19	381
2022 Q4	129,468,465	$7,364,542,615	-$117,989,602	$8,170,840	$26,120,540	$56.90	414
2022 Q3	131,997,507	$5,220,452,246	+$129,179,246	$3,254,000	$7,627,000	$39.54	345
2022 Q2	128,322,139	$5,647,663,757	+$24,849,414	$2,578,000	$7,627,910	$44.00	359
2022 Q1	128,337,653	$5,115,592,058	-$42,336,732	$2,812,000	$14,054,000	$39.88	298
2021 Q4	129,389,920	$5,202,313,554	-$77,902,534	$5,217,000	$15,418,510	$40.21	314
2021 Q3	130,048,093	$5,289,784,296	+$44,615,821	$5,668,000	$14,693,000	$40.68	316
2021 Q2	129,727,357	$5,890,257,760	-$85,620,767	$17,359,000	$18,003,000	$45.41	309
2021 Q1	132,146,550	$5,510,245,951	-$141,977,795	$12,004,000	$12,177,000	$41.69	329
2020 Q4	136,300,724	$5,821,984,170	+$126,547,922	$5,352,000	$17,134,000	$42.71	335
2020 Q3	133,950,846	$3,522,042,268	-$34,152,841	$4,710,000	$9,748,000	$26.28	262
2020 Q2	135,245,376	$3,623,665,867	+$159,039,078	$6,684,000	$25,921,000	$26.81	256
2020 Q1	130,660,067	$2,348,012,984	+$56,330,665	$4,236,000	$6,463,000	$17.99	205
2019 Q4	127,472,754	$2,260,145,336	+$7,244,846	$6,506,000	$16,410,000	$17.73	218
2019 Q3	126,453,885	$1,961,243,729	+$54,882,291	$4,501,000	$9,786,000	$15.51	206
2019 Q2	122,604,908	$2,104,656,029	+$207,889,231	$2,065,000	$11,432,000	$17.18	199
2019 Q1	121,175,132	$1,950,961,461	+$3,424,262	$2,669,000	$7,802,000	$16.10	198
2018 Q4	120,370,571	$1,760,962,328	-$41,616,936	$4,212,000	$7,147,000	$14.63	186
2018 Q3	122,639,238	$2,228,291,177	+$6,384,296	$4,033,000	$7,155,000	$18.17	191
2018 Q2	122,789,328	$2,071,554,889	-$21,158,536	$4,487,000	$7,622,000	$16.87	193
2018 Q1	123,600,167	$2,421,268,422	+$15,633,634	$9,928,000	$25,329,000	$19.59	208
2017 Q4	122,499,248	$2,482,081,024	+$20,859,736	$20,085,000	$42,169,000	$20.26	196
2017 Q3	121,459,215	$2,109,824,400	-$3,854,105	$4,101,000	$33,775,000	$17.37	164
2017 Q2	121,956,653	$1,561,931,486	+$88,012,978	$2,569,000	$21,871,000	$12.82	164
2017 Q1	115,142,534	$1,492,238,870	+$198,524,663	$5,026,000	$15,983,000	$12.96	155
2016 Q4	110,724,726	$1,093,967,390	+$44,483,048	$16,911,000	$8,941,000	$9.88	164
2016 Q3	106,009,210	$1,279,976,335	+$17,256,778	$3,687,000	$9,370,000	$12.08	161
2016 Q2	104,978,572	$906,530,216	+$19,234,625	$2,415,000	$9,308,000	$8.63	159
2016 Q1	102,642,856	$973,879,684	+$1,362,632	$3,716,000	$15,920,000	$9.47	159
2015 Q4	98,841,329	$1,712,905,548	+$8,221,079	$15,211,000	$18,492,000	$17.33	164
2015 Q3	98,182,404	$1,318,661,570	+$3,328,652	$9,398,000	$14,038,000	$13.43	174
2015 Q2	97,583,561	$2,203,565,952	+$80,075,442	$16,215,000	$30,710,000	$22.58	158
2015 Q1	94,411,049	$1,348,555,169	+$51,544,544	$6,903,000	$9,903,000	$14.28	137
2014 Q4	91,157,821	$879,597,787	+$20,012,260	$9,989,000	$5,975,000	$9.65	130
2014 Q3	88,971,177	$809,677,785	+$28,690,375	$9,001,000	$9,716,000	$9.10	118
2014 Q2	85,679,010	$846,469,840	-$18,616,849	$7,877,000	$9,955,000	$9.88	127
2014 Q1	85,850,619	$1,090,677,475	+$78,418,989	$11,138,000	$8,815,000	$12.70	129